MLTX Latest Headlines

MoonLake Immunotherapeutics Prices Upsized $200 Million Offering to Advance Sonelokimab Development

Market Chameleon (Wed, 24-Jun 8:10 AM)

MoonLake's Sonelokimab Achieves Leading Clinical Outcomes at One Year—Data Signals Promise for HS Patients

Market Chameleon (Mon, 22-Jun 11:44 AM)

MoonLake's Sonelokimab Delivers Leading Efficacy and Quality-of-Life Gains in Phase 3 HS Trial as FDA Filing Nears

Market Chameleon (Mon, 22-Jun 7:06 AM)

MoonLake Immunotherapeutics Aligns with FDA—Label for Sonelokimab in HS Could Set New Clinical Standards

Market Chameleon (Mon, 11-May 7:07 AM)